Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill for chronic hives tested in thousands of real patients

NCT ID NCT07358364

First seen Jan 25, 2026 · Last updated May 24, 2026 · Updated 17 times

Summary

This study follows about 3,280 adults with chronic spontaneous urticaria (long-lasting hives with no clear trigger) to see how well remibrutinib works in real-world clinics. Participants either stay on standard antihistamines or switch to remibrutinib, based on their doctor's decision. Researchers will track hive control and side effects for 24 months to understand the drug's everyday effectiveness and safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Cleaver Dermatology

    RECRUITING

    Kirksville, Missouri, 63501, United States

Conditions

Explore the condition pages connected to this study.